ZURICH (Reuters) Jul 15 - Roche said on Monday it had received conditional approval from the European Commission for Erivedge (vismodegib), for adults with metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery or radiotherapy
The approval makes Erivedge the first licensed medicine for patients in the European Union with this form of skin cancer, Roche said. In January 2012, Erivedge became the first licensed medicine for advanced BCC in the United States. Since October 2012, Erivedge has been approved in Switzerland, Australia, Israel, South Korea, Mexico and Ecuador.
Under the provisions of the conditional European approval, Roche will provide additional data on Erivedge in advanced BCC from an ongoing trial.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου